Search Results
Your search for Matthew Stenger matches 7644 pages
Showing 901 - 950Longitudinal ctDNA Methylation Status and Risk of Recurrence After Surgery in Patients With Stage I to III Colorectal Cancer
In a Chinese study reported in JAMA Oncology, Mo et al found that longitudinal measurement of circulating tumor DNA (ctDNA) methylation permitted early detection of disease recurrence in patients undergoing surgery for stage I to III colorectal cancer. Study Details In the prospective cohort...
Encorafenib and Binimetinib in BRAF V600E–Mutant Metastatic NSCLC
In the phase II PHAROS trial reported in the Journal of Clinical Oncology, Gregory J. Riely, MD, PhD, and colleagues found that the combination of encorafenib and binimetinib showed activity in both treatment-naive and previously treated patients with BRAF V600E–mutant metastatic non–small cell...
Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and After Treatment for High-Risk Breast Cancer: Association With Recurrence and Mortality
In a study reported in JAMA Network Open, Cannioto et al found that greater adherence to cancer prevention lifestyle recommendations before, during, and after treatment for high-risk breast cancer was associated with a reduced risk of disease recurrence and all-cause mortality. Study Details The...
Food Deserts, Food Swamps, and Obesity-Related Cancer Mortality in the United States
In a study reported in JAMA Oncology, Bevel et al found that residing in U.S. areas defined as food deserts (less access to grocery stores) or food swamps (high access to fast foods) was associated with an increased risk of obesity-related cancer mortality. Study Details The study used Department...
S-1 Chemoradiotherapy for Older Patients With Inoperable Esophageal Squamous Cell Carcinoma
In a Chinese phase III trial reported in JAMA Network Open, Wang et al found that oral S-1 chemotherapy given with simultaneous integrated boost radiotherapy (SIB-RT) and following SIB-RT improved overall survival in patients aged 70 or older with inoperable esophageal squamous cell carcinoma....
Adagrasib in Treatment of KRAS G12C–Mutated Advanced Solid Tumors
As reported in the Journal of Clinical Oncology by Tanios S. Bekaii-Saab, MD, and colleagues, findings in the phase II cohort of the KRYSTAL-1 trial showed activity of adagrasib in patients with KRAS G12C–mutated advanced solid tumors. As noted by the investigators, the KRAS G12C inhibitor...
Perioperative Palliative Care and Health-Related Quality of Life in Patients Undergoing Curative-Intent Surgery for Upper Gastrointestinal Cancers
In a study reported in JAMA Network Open, Aslakson et al found that perioperative surgeon/palliative care team co-management did not improve health-related quality of life vs surgeon team management alone in patients undergoing curative-intent surgery for upper gastrointestinal cancers. Study...
Trauma and Long-Term Risk of Death or Immune-Mediated Disease or Cancer in Twin Pairs
In a Danish study reported in JAMA Surgery, Eskesen et al found moderate to severe physical trauma in one of same-sex twins was associated with an increased risk of the composite endpoint of death or immune-mediated disease or cancer vs their co-twins over long-term follow-up. Study Details The...
Risk Factors for Primary Bone Cancer in Childhood Cancer Survivors: Bone Tissue Radiation Exposure and Alkylating Agent Dose
In a case-control study reported in the Journal of Clinical Oncology, Reulen et al found that an increased risk of primary bone cancer was associated with increasing radiation dose to bone tissue and increasing alkylating agent dose among survivors of childhood cancer. As noted by the...
Effect of Cancer History on Disability, Unemployment, and Medical Expenditures
In a cross-sectional study reported in JAMA Network Open, Grabowski et al found that among U.S. adults, a history of cancer was associated with an increased risk of disability and unemployment payments and higher medical expenditures. Study Details The study used data from the Medical Expenditure...
Noncovalent BTK Inhibitor Pirtobrutinib in Patients With Mantle Cell Lymphoma Previously Treated With Covalent BTK Inhibitors
In the phase I/II BRUIN trial reported in the Journal of Clinical Oncology, Michael Wang, MD, and colleagues found that the noncovalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib produced durable responses in patients with mantle cell lymphoma who were previously treated...
Factors Associated With Nonadherence to Lung Cancer Screening Recommendations
In a single-institution retrospective cohort study reported in JAMA Network Open, Lin et al identified factors associated with nonadherence to lung cancer screening recommendations among patients undergoing screening—and found that negative findings on two successive screenings were associated with ...
Fecal Microbiota Transplantation: Its Role for Patients Undergoing Allogeneic HCT and Receiving Induction Therapy for AML
In a single-institution phase II study reported in the Journal of Clinical Oncology, Rashidi et al found that fecal microbiota transplantation (FMT) did not reduce the risk of infection in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) or patients with acute myeloid...
Accumulation of Chronic Comorbidities Among Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Esbenshade et al found that survivors of childhood cancer were more likely to accumulate comorbidities over time than their siblings or the general population. Study Details In the study, Cumulative Illness Rating Scale for Geriatrics...
Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Platinum-Resistant or Platinum-Refractory Ovarian Cancer
In the phase II VIRO-15 trial reported in JAMA Oncology, Holloway et al found that virotherapy with the modified oncolytic vaccinia virus olvimulogene nanivacirepvec plus platinum-based chemotherapy with or without bevacizumab showed activity in patients with platinum-resistant or...
Risk of Dementia and Mortality With BCG Vaccine in Non–Muscle-Invasive Bladder Cancer
In a study reported in JAMA Network Open, Weinberg et al found that receipt of the bacillus Calmette-Guérin (BCG) vaccine in patients with non–muscle-invasive bladder cancer was associated with a lower risk of Alzheimer’s disease and related dementias—as well as a lower risk of mortality—compared...
Polatuzumab Vedotin-piiq for Previously Untreated DLBCL–Not Otherwise Specified and High-Grade B-Cell Lymphoma
On April 19, 2023, polatuzumab vedotin-piiq was approved for use with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for patients with diffuse large B-cell lymphoma (DLBCL)–not otherwise specified or those with high-grade B-cell lymphoma who have an International...
Interruption of Endocrine Therapy to Attempt Pregnancy in Women With Hormone Receptor–Positive Early Breast Cancer
In a study reported in The New England Journal of Medicine, Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and colleagues found that temporary interruption of adjuvant endocrine therapy to attempt pregnancy was not associated with increased short-term risk of breast cancer events among ...
Endocrine Therapy Switch With or Without Ribociclib After Disease Progression on Endocrine Therapy and CDK4/6 Inhibition for Metastatic Breast Cancer
In the phase II MAINTAIN trial reported in the Journal of Clinical Oncology, Kevin Kalinsky, MD, MS, and colleagues found that a switch in endocrine therapy plus continued CDK4/6 inhibitor treatment with ribociclib was associated with improved progression-free survival in patients with hormone...
5α-Reductase Inhibitor Use and Progression of Bladder Cancer in South Korean Males
In a Korean cohort study reported in JAMA Network Open, An et al found that men with prescriptions for 5α-reductase inhibitors prior to diagnosis of urothelial bladder cancer had better outcomes than those with no prior prescriptions. Study Details The study analyzed patient claims data from the...
Anthracycline-Related Cardiomyopathy and HP Gene Expression in Childhood Cancer Survivors
In a study reported in JACC: CardioOncology, Singh et al found that haptoglobin (HP) gene expression was associated with risk of anthracycline-related cardiomyopathy in childhood cancer survivors. Study Details In the study, messenger RNA sequencing was performed on total RNA from the peripheral...
Allostatic Load and Mortality in Patients With Breast Cancer
In a study reported in JAMA Network Open, Samilia Obeng-Gyasi, MD, MPH, and colleagues found that allostatic load—defined as “a cumulative measure of physiologic damage secondary to cognitive-emotional responses and perceptions to socioenvironmental stressors (ie, low socioeconomic status)”—was...
Microdoses of Incisional Antibiotics and Surgical Site Infections in Surgery for Skin Cancer
In a single-institution study conducted in New Zealand reported in JAMA Surgery, Goh et al found that microdoses of incisional antibiotics may reduce the risk of surgical site infections during surgery for skin cancer, as well as reduce the risk of infections requiring postoperative systemic...
SGLT2 Inhibitors and Cardiovascular Outcomes in Older, Anthracycline-Treated Patients With Cancer
In a population-based cohort study reported in JACC: CardioOncology, Abdel-Qadir et al found that receipt of sodium glucose cotransporter-2 (SGLT2) inhibitors was associated with a reduced risk of hospitalization for heart failure—but not risk for heart failure—among patients aged ≥ 65 years with...
Diffusing Alpha-Emitter Radiation Therapy for Recurrent or Unresectable Skin Cancers
In a small study reported in JAMA Network Open, D’Andrea et al found that diffusing alpha-emitter radiation therapy—a novel solid tumor management strategy using alpha-particle interstitial brachytherapy—appeared to be safe and showed activity in patients with recurrent or unresectable skin...
Addition of First-Line Dalpiciclib to Letrozole or Anastrozole in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In an interim analysis of a Chinese phase III trial (DAWNA-2) reported in The Lancet Oncology, Zhang et al found that the addition of the CDK4/6 inhibitor dalpiciclib to letrozole or anastrozole improved progression-free survival as first-line treatment in patients with advanced hormone...
Long-Term Outcomes With Single-Fraction vs Multifraction SABR for Pulmonary Oligometastases
As reported in the Journal of Clinical Oncology by Shankar Siva, PhD, and colleagues, long-term outcomes of the Trans Tasman Radiation Oncology Group (TROG) 13.01 SAFRON II phase II trial showed no difference in overall survival with single-fraction vs multifraction stereotactic ablative body...
MGMT Promoter Methylation and Survival Outcomes in Low-Grade and Anaplastic Gliomas After Alkylating Chemotherapy
In a study reported in JAMA Oncology, Kinslow et al found that MGMT promoter methylation (mMGMT) was associated with improved survival outcomes in patients receiving alkylating chemotherapy for low-grade and anaplastic gliomas. Study Details The study involved 411 patients with grade II or III...
Tumor Genomic Profile and Risk for Arterial Thromboembolism in Patients With Solid Cancer
In a single-institution study reported in JACC: CardioOncology, Stephanie Feldman, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that somatic KRAS and STK11 alterations were associated with increased risk of arterial thromboembolism in patients with solid tumors,...
Survival in Patients With Neuroblastoma on Reduced Therapy as a Result of Change in COG Risk Stratification
In an analysis recently reported in the Journal of Clinical Oncology,1 Bender et al found that “excellent” survival outcomes were achieved in patients receiving reduced treatment for neuroblastoma as a result of reassignment to intermediate risk from high risk based on a change in the minimum age...
Circulating Tumor DNA Identified Prior to and During Treatment Is Associated With Poorer Outcomes in Primary CNS Lymphoma
In a collaborative study from the University of Freiburg and Stanford University reported in the Journal of Clinical Oncology, Jurik A. Mutter, BSc, of the Faculty of Medicine, University of Freiburg, and colleagues found that circulating tumor DNA (ctDNA) identified prior to and during treatment...
Effect of HER2 Expression Levels on Survival Outcomes in Patients With Metastatic Breast Cancer Receiving Targeted Therapy Plus Endocrine Therapy
In a single-institution cohort study reported in JAMA Network Open, Jason A. Mouabbi, MD, and colleagues found no difference in survival outcomes between patients with hormone receptor–positive metastatic breast cancer with low vs no HER2 expression who received targeted therapy and endocrine...
Anti–PD-L1 Combination vs Sunitinib in Metastatic Renal Cell Carcinoma
In a meta-analysis reported in a research letter in JAMA Network Open, Maiorano et al found that first-line anti–PD-L1 treatment combinations did not significantly improve overall survival vs sunitinib in patients with metastatic renal cell carcinoma. A progression-free survival benefit was...
Prevalence of Functional Limitations in U.S. Cancer Survivors
In a study reported in a research letter in JAMA Oncology, Patel et al found that the prevalence of self-reported functional limitations in U.S. cancer survivors increased between 1999 and 2018. Study Details The analysis included adults in the 1999 to 2018 National Health Interview Survey (NHIS)...
Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
On March 22, 2023, the anti–PD-1 antibody retifanlimab-dlwr was granted accelerated approval for adults with metastatic or recurrent locally advanced Merkel cell carcinoma.1 Supporting Efficacy Data Approval was based on findings in POD1UM-201 (ClinicalTrials.gov identifier NCT03599713), a...
Omidubicel-onlv to Reduce Time to Neutrophil Recovery and Incidence of Infection in Hematologic Malignancies
On April 17, 2023, omidubicel-onlv was approved for use in adult and pediatric patients (≥ 12 years) with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.1 ...
Tumor Mutational Burden and Outcomes in Patients With Advanced Cancers Treated With Immune Checkpoint Inhibitors
In a study reported in JAMA Network Open, Charu Aggarwal, MD, MPH, and colleagues found that patients with advanced solid cancers and a high tumor mutational burden (TMB-H) had improved overall survival with immune checkpoint inhibitor therapy vs those with a low tumor mutational burden (TMB-L)....
Addition of Panitumumab to Trifluridine/Tipiracil in Anti-EGFR Treatment Rechallenge in Refractory RAS Wild-Type Metastatic Colorectal Cancer
In the Italian phase II VELO trial reported in JAMA Oncology, Napolitano et al found that anti-EGFR treatment rechallenge with the addition of panitumumab to trifluridine/tipiracil improved progression-free survival in the third-line setting for patients with RAS wild-type metastatic colorectal...
Radical Cystectomy vs Trimodality Therapy for Muscle-Invasive Bladder Cancer
In a retrospective analysis reported in The Lancet Oncology, Zlotta et al found that trimodality therapy was associated with similar outcomes compared to radical cystectomy in patients with muscle-invasive bladder cancer. Study Details The study involved 722 patients with clinical stage T2–T4N0M0...
Assay Prediction of pCR in Patients With HER2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
In an analysis reported in JAMA Oncology, Waks et al found that the HER2DX assay performed well in predicting the likelihood of pathologic complete response (pCR) in patients with early HER2-positive breast cancer receiving de-escalated neoadjuvant treatment with paclitaxel, trastuzumab, and...
Multisystem Inflammatory Syndrome in Children With Cancer and COVID-19
In a U.S. cohort study reported in JAMA Oncology, Martin et al described the clinical course and potential factors associated with post–COVID-19 multisystem inflammatory syndrome in children with cancer also infected with COVID-19. Post–COVID-19 multisystem inflammatory syndrome is a...
Late Major Surgical Intervention in Survivors of Childhood Cancer
In an analysis from the Childhood Cancer Survivor Study (CCSS) reported in The Lancet Oncology, Dieffenbach et al found that childhood cancer survivors had a heavy cumulative burden of late major surgical interventions. Study Details The study involved data from the CCSS on 5-year survivors of...
Specialist Palliative Care for Patients Undergoing Major Abdominal Surgery for Cancer
In a single-center trial reported in JAMA Surgery, Shinall et al found that specialist palliative care did not improve quality of life or survival vs usual care in patients undergoing nonpalliative major abdominal surgery for cancer. Study Details In the trial, 235 patients scheduled for specified...
Augmented Early Intensification and Higher Consolidation Methotrexate Dosing Show No Benefit in Childhood ALL
Results of the Intercontinental-Berlin-Frankfurt-Münster 2009 trial in childhood acute lymphoblastic leukemia (ALL) were reported in the Journal of Clinical Oncology by Campbell et al. Findings included no benefit of augmented early intensification in intermediate-risk or high-risk patients and no...
Use of 5α-Reductase Inhibitors and Prostate Cancer Mortality
In a systematic review and meta-analysis reported in JAMA Oncology, Baboudjian et al found no significant association between the use of 5α-reductase inhibitors (5-ARIs) and the risk of prostate cancer mortality. As stated by the investigators, “Recently, several large, high-quality analyses have...
First-Line Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL
In the phase III GAIA–CLL13 trial reported in The New England Journal of Medicine, Barbara Eichhorst, MD, and colleagues found better outcomes with venetoclax plus obinutuzumab and venetoclax, obinutuzumab, and ibrutinib compared with chemoimmunotherapy as first-line treatment in fit patients with ...
Trastuzumab/Pertuzumab Plus Neoadjuvant Paclitaxel or Endocrine Therapy in Hormone Receptor–Positive, HER2-Positive Early Breast Cancer
In a German phase II trial (WSG-TP-II) reported in JAMA Oncology, Gluz et al found that the addition of neoadjuvant paclitaxel monotherapy to trastuzumab/pertuzumab resulted in a higher pathologic complete response (pCR) rate in patients with hormone receptor–positive, HER2-positive early breast...
Implantable Ultrasound Device to Open Blood-Brain Barrier for Peritumoral Delivery of Albumin-Bound Paclitaxel in Recurrent Glioblastoma
In a small single-institution phase I trial reported in The Lancet Oncology, Sonabend et al found that an implantable device for low-intensity pulsed ultrasound with concomitant administration of intravenous microbubbles (LIPU-MB) may be safely used to open the blood-brain barrier to permit...
Does Prediagnosis Smoking Cessation Improve Overall Survival in Patients With NSCLC?
In a cohort study reported in JAMA Network Open, Wang et al found that overall survival in patients with non–small cell lung cancer (NSCLC) who stopped smoking prior to their cancer diagnosis was better than overall survival among those who were current smokers at the time of their diagnosis. Study ...
Addition of Bevacizumab to Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer
As reported in The New England Journal of Medicine by Prager et al, the phase III SUNLIGHT trial has shown prolonged overall survival with the addition of bevacizumab to trifluridine/tipiracil (FTD-TPI) in previously treated patients with metastatic colorectal cancer. As stated by the...
